Global Proteomics Market - Focused Insights 2024-2029

MARKET INSIGHTS

The global proteomics market was valued at USD 32.39 billion in 2023 and is expected to reach USD 67.22 billion by 2029, growing at a CAGR of 12.94% during the forecast period. The proteomics market is characterized by intense competition and rapid growth, fueled by the increasing prevalence of chronic and genetic diseases, the shift towards personalized therapies, and advancements in proteomic technologies. Proteomics, the comprehensive study of proteomes, provides insights into protein function and structure, surpassing genomic analysis. It is essential in biomedical science, with key applications in drug development, disease diagnostics, and therapeutic interventions.

MARKET DRIVERS & OPPORTUNITIES

Increased Focus on High Throughput Proteomics and Associated Systems

High-Throughput Proteomics (HTP) employs automated analytical methods for comprehensive protein analysis. Recent advancements in mass spectrometry, including speed, sensitivity, and precision, alongside improved sample preparation and data analysis, are propelling HTP forward. Data-Independent Acquisition (DIA) provides unbiased proteome analysis and reproducible results across large sample sets. High-throughput mass spectrometry continues to evolve, enabling researchers to analyze complex proteomes with enhanced accuracy and sensitivity, facilitating discoveries in drug development and biomarker identification.

Introduction of Innovative Technologies and Methods in Proteomics Study

Emerging methods for monitoring post-translational modifications (PTMs) are significantly advancing proteomics. In biological systems, protein function can vary greatly due to PTMs, even when protein concentration is unchanged. The development of innovative PTM monitoring techniques is essential for a comprehensive understanding of protein function.

Emergence of Personalized Medicines

Personalized medicine, utilizing individual molecular profiles, is driving demand for proteomics research. Proteomics, by studying proteins and their characteristics, facilitates the development of tailored treatments. This approach aims to enhance efficacy, reduce side effects, and improve cost-effectiveness. Proteomics plays a crucial role in personalized medicine, from biomarker identification to drug development.

INDUSTRY RESTRAINTS

Access Denied hindering the Proteome's Full Potential

The proteome exhibits greater dynamic range and complexity than the genome or transcriptome due to extensive post-translational modifications. While approximately 20,000 human genes generate over a million protein variants through transcription and translation, further chemical modifications significantly increase proteome diversity. Traditional technologies struggle to measure this complexity, but modern proteomics methods are capable of rapid, large-scale analysis of the proteome's breadth and depth.

GLOBAL PROTEOMICS MARKET INSIGHTS

• Insight By Product Type: The consumables and reagents segment dominated the global proteomics market in 2023, holding over 76% market share. This segment's growth is driven by the complex nature of proteomics, which requires extensive consumables and reagents for sample preparation and protein analysis. The lack of standardized MS sample preparation methods further increases demand for diverse consumables, which are often single-use and necessitate continuous replenishment.
• Insight By Applications: The forensics and applied proteomics segment is the fastest-growing in the global proteomics market, with a CAGR of 14.31%. Proteomics has revolutionized forensic science by enabling protein characterization and identification for diverse applications. Analyzing postmortem samples enhances forensic autopsy and pathology. Proteins, stable and abundant in biological evidence, provide critical information for criminal investigations. Historically, protein analysis has been used for body fluid identification, species determination, and human identification.
• Insight By End-Users: Pharma and biotech companies held the largest share of the global proteomics market, primarily due to their significant R&D investments in personalized medicine. These companies utilize proteomics technologies extensively in R&D to create proteomics-based products. The increasing shift from genomics to proteomics is fueling the market, as proteomic studies offer crucial insights for drug discovery, biomarker identification, and targeted therapy development, solidifying proteomics' role as a gold standard.

GEOGRAPHICAL ANALYSIS

North America dominates the proteomics market, driven by chronic disease prevalence, personalized medicine demand, healthcare expenditure, and R&D funding. These factors, particularly chronic conditions like cancer and diabetes, are also fueling proteomics research. While holding the third-largest share, APAC is the fastest-growing market. Life sciences expansion, healthcare advancements, increased R&D, and personalized medicine focus are key drivers. Rising healthcare spending in APAC and demand for personalized care in countries like Japan and China are accelerating proteomics studies.

COMPETITIVE LANDSCAPE

The global proteomics market, featuring 37 vendors, is characterized by intense competition among established leaders, emerging players, and growing companies. Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific, Danaher, PerkinElmer, and BGI Group are key players with substantial market share. These vendors prioritize expanding their proteomics offerings to address client requirements, adhere to international regulations, improve product efficiency, and reinforce their market presence.

RECENT VENDORS ACTIVITIES

Recent activity in the proteomics market includes significant acquisitions and strategic partnerships.

• In 2024, Thermo Fisher Scientific acquired Olink Holding AB, a leader in next-generation proteomics solutions.
• In 2023, Danaher acquired Abcam for approximately USD 5.7 billion, enhancing its proteomics tools and reagents portfolio.
• In 2023, SomaLogic and Standard BioTools Inc. announced an all-stock merger, while Bruker Corporation and Biognosys AG formed a strategic partnership focusing on 4D proteomics technology.